Today: October 26, 2016, 9:15 pm

"Dr Fischer Pharm Labs Ltd in Beauty and Personal Care (Israel)" now available at Fast Market Research

New Consumer Goods research report from Euromonitor International is now available from Fast Market Research 2014-08-19 09:10:10
During 2013, the main focus of Dr Fischer's strategy is set to remain fixed on anti-ageing ingredients for skin care products and organic components for baby and child-specific products. The company's strategy is to continue developing new technologically advanced anti-ageing products in order to maintain its professional positioning. Moreover, the company is expected to attempt to gain value share in sun care in the US.

Euromonitor International Local Company Profiles are a concise set of briefings detailing the strategic direction taken by a company. Discover key contact details, the company background and their competitive positioning through this collection of snapshot company profiles.

Full Report Details at
- ..

Product coverage: Baby and Child-specific Products, Bath and Shower, Colour Cosmetics, Deodorants, Depilatories, Fragrances, Hair Care, Mass Beauty and Personal Care, Men's Grooming, Oral Care, Oral Care Excl Power Toothbrushes, Premium Beauty and Personal Care, Sets/Kits, Skin Care, Sun Care.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Reasons to Get this Report:

* Get a detailed picture of the Beauty and Personal Care market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market's major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Report Table of Contents:

Strategic Direction
Key Facts
Summary 1 Dr Fischer Pharm Labs: Key Facts
Company Background
Competitive Positioning
Summary 2 Dr Fischer Pharm Labs: Competitive Position 2013

About Euromonitor International

Euromonitor International is a world leading independent provider of business intelligence on industries, countries and consumers. Their business intelligence products include award-winning online information databases, market reports and business reference books. Founded in 1972, Euromonitor International is a privately owned company with offices in London, Chicago, Singapore, Shanghai and Vilnius. Euromonitor has a team of over 600 in-country analysts worldwide, giving them a unique capability to deliver high quality and reliable business information. View more research from Euromonitor International at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Press Information

Published by
Bill Thompson

# 508 Words
Related Articles
More From Business
Willis Lease Finance Purchases the Business and [..]
NOVATO, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (Nasdaq:WLFC) announced today that its wholly [..]
Thomson Reuters: Media Advisory - 2016 U.S. [..]
NEW YORK, October 26, 2016 - Join us for live analysis with leading Reuters journalists as they discuss the political [..]
Medtronic Announces FDA Approval of New Recaptureable [..]
Launch of 34 mm Self-Expanding Evolut R Device Expands TAVR Treatment to Patients Who Could Not be Treated Previously DUBLIN [..]
FIMALAC : Revenue for the first nine [..]
Fimalac's consolidated revenue for the nine months ended September 30, 2016 totaled €226.2 million compared with €131.2 [..]
Almere, The NetherlandsOctober 26, 2016 ASM International N.V. (Euronext Amsterdam: ASM) today reports its third quarter 2016 [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.